Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
5
2
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
20.0%
1 terminated out of 5 trials
50.0%
-36.5% vs benchmark
20%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Extended Access of Momelotinib in Adults With Myelofibrosis
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib